[Current strategies in radiotherapy for cervical and endometrial carcinoma].
We used combinations of taxan-based neoadjuvant and adjuvant full-dose chemotherapy and aggressive combined radiotherapy including clinical target volume extension, increased total dosage, hyperthermia, cryo- and local chemotherapy as radiosensitizers, for treatment of invasive and locally-advanced breast cancer or endometrial carcinoma with poor prognosis. 3D-ultrasound/CT/MRI--based designing of radiotherapy and monitoring of dynamic definition of target volume and "high risk volume" in organs at risk in cases of tumor progression was an indispensable measure. As a result, no local recurrence was reported in 73% for 36 months.
Titova
V A
VA
Kharchenko
N V
NV
Dobrovol'skaia
N Iu
NIu
Kreĭnina
Iu M
IuM
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy; D002277:Carcinoma / Q000532:radiotherapy* / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D017679:Cryotherapy; D016889:Endometrial Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D021621:Imaging, Three-Dimensional; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014463:Ultrasonography; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents